Tokyo, November 13, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been named for the first time to the CDP¹ Japan 500 Climate Disclosure Leadership Index (CDLI) in recognition of its perfect score on the disclosure of information related to climate change.

CDP surveys and analyzes climate change strategies at 500 of Japan’s largest companies within the FTSE Japan Index². The top 50 highest-scoring respondents earn a place in the CDLI, and Astellas was named this year with a perfect disclosure with a score of 100.

Through CSR activities including the initiative for climate change, Astellas will continue its efforts to contribute to the sustainable development of society and consequently enhance its enterprise value.

¹⁾ CDP (www.cdp.net): Formerly Carbon Disclosure Project, is an international, not-for-profit organization providing the only global system for companies and cities to measure, disclose, manage and share vital environmental information.

²⁾ FTSE Japan Index: The Japanese version of the global equity index that is highly trusted worldwide. It is provided by FTSE, which develops indices and is wholly-owned by the London Stock Exchange.

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.